Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors by Delcuve, Geneviève P et al.
REVIEW Open Access
Roles of histone deacetylases in epigenetic
regulation: emerging paradigms from studies
with inhibitors
Geneviève P Delcuve, Dilshad H Khan and James R Davie
*
Abstract
The zinc-dependent mammalian histone deacetylase (HDAC) family comprises 11 enzymes, which have specific
and critical functions in development and tissue homeostasis. Mounting evidence points to a link between
misregulated HDAC activity and many oncologic and nononcologic diseases. Thus the development of HDAC
inhibitors for therapeutic treatment garners a lot of interest from academic researchers and biotechnology
entrepreneurs. Numerous studies of HDAC inhibitor specificities and molecular mechanisms of action are ongoing.
In one of these studies, mass spectrometry was used to characterize the affinities and selectivities of HDAC
inhibitors toward native HDAC multiprotein complexes in cell extracts. Such a novel approach reproduces in vivo
molecular interactions more accurately than standard studies using purified proteins or protein domains as targets
and could be very useful in the isolation of inhibitors with superior clinical efficacy and decreased toxicity
compared to the ones presently tested or approved. HDAC inhibitor induced-transcriptional reprogramming,
believed to contribute largely to their therapeutic benefits, is achieved through various and complex mechanisms
not fully understood, including histone deacetylation, transcription factor or regulator (including HDAC1)
deacetylation followed by chromatin remodeling and positive or negative outcome regarding transcription
initiation. Although only a very low percentage of protein-coding genes are affected by the action of HDAC
inhibitors, about 40% of noncoding microRNAs are upregulated or downregulated. Moreover, a whole new world
of long noncoding RNAs is emerging, revealing a new class of potential targets for HDAC inhibition. HDAC
inhibitors might also regulate transcription elongation and have been shown to impinge on alternative splicing.
Keywords: histone deacetylase, HDAC, HDAC inhibitors, HDAC complexes, gene expression, noncoding RNAs,
epigenetics
Introduction
Acetylation of the lysine ε-amino group, first discovered
on histones, is a dynamic posttranslational modification
(PTM) regulated by the opposing activities of lysine
acetyltransferases (KATs) and histone deacetylases
(HDACs). Histone acetylation is a modulator of chroma-
tin structure involved in DNA replication, DNA repair,
heterochromatin silencing and gene transcription [1,2].
Hyperacetylation usually marks transcriptionally active
genes, as it contributes to the decondensed chromatin
state and maintains the unfolded structure of the tran-
scribed nucleosome [2-6]. Moreover, specific acetylated
sites on core histones are read by bromodomain mod-
ules found in proteins, and sometimes in KATs, which
are components of chromatin-remodeling complexes
involved in transcriptional activation [7]. Conversely,
HDACs are found in corepressor complexes and, by
removing acetyl groups from histones, induce the for-
mation of a compacted, transcriptionally repressed chro-
matin structure. As discussed below, however, this
model reflects quite an oversimplification of the role of
HDACs in transcription regulation.
Many nonhistone proteins (transcription factors, regu-
lators of DNA repair, recombination and replication,
chaperones, viral proteins and others) are also subject to
acetylation [8-10]. Investigators in a recent study used
high-resolution mass spectrometry to identify 3,600
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that lysine acetylation is implicated in the regulation of
nearly all nuclear functions and many cytoplasmic pro-
cesses [11]. Furthermore, acetylation is regulated by
and/or regulates other PTMs. Through either recruit-
ment or occlusion of binding proteins, PTMs may lead
to or prevent a secondary PTM on histones and nonhis-
tone proteins [12,13]. In particular, histone H3 phos-
phorylation on serine 10 or 28, rapid and transient
PTMs in response to the stimulation of signaling path-
ways such as the mitogen-activated protein kinase
(MAPK) pathways, are associated with histone acetyla-
tion and transcriptional activation of specific genes [14].
A cross-talk also exists between histone acetylation and
H3 methylation. Although acetylation is generally linked
to transcription activation, the effect of methylation
depends on which amino acid residue is modified and
the degree to which this residue is methylated (mono-,
di- or trimethylation of lysine). Methylation of H3 lysine
4 or 36 is associated with transcription activation, but
methylation of lysine 9 or 27 is linked to transcription
repression [15,16].
To date, 18 different mammalian HDACs have been
identified and divided into four classes based on their
sequence similarity to yeast counterparts [17,18].
HDACs from the classical family are dependent on Zn
2+
for deacetylase activity and constitute classes I, II and
IV. Class I HDACs, closely related to yeast RPD3, com-
prise HDAC1, HDAC2, HDAC3 and HDAC8. Class II
HDACs, related to yeast HDA1, are divided into sub-
class IIa (HDAC4, HDAC5, HDAC7 and HDAC9) and
subclass IIb (HDAC6 and HDAC10). Class IV contains
only HDAC11. Class III HDACs consist of seven sir-
tuins, which require the NAD
+ cofactor for activity.
Inhibitors of Zn
2+-dependent HDACs were originally
discovered as inducers of transformed cell growth arrest
and cell death and only later were identified as inhibi-
tors of HDAC activity [19]. It was recognized that
HDACs are upregulated in many cancers or aberrantly
recruited to DNA following chromosomal transloca-
tions, particularly in hematologic malignancies [20,21].
The specificity of HDAC inhibitors toward tumor cells,
although poorly understood, has led to their develop-
ment as anticancer drugs. More recently, clinical studies
using HDAC inhibitors have been extended to a range
of nononcologic diseases, such as sickle cell anemia,
HIV infection, cystic fibrosis, muscular dystrophy and
neurodegenerative and inflammatory disorders [21-23].
The use of HDAC inhibitors also constitutes a chemical
approach to the study of HDAC cellular functions. In
addition, crucial developmental and physiological roles
of HDACs have been elucidated by knockout studies
[21,24]. The scope of this review concerns emerging
concepts regarding the roles of HDACs in modulating
chromatin structure and function as revealed by studies
with HDAC inhibitors.
Class I HDAC complexes
Class I HDACs are ubiquitously expressed nuclear
enzymes, although HDAC8 is generally poorly expressed
[17]. Except for HDAC8, class I HDACs are compo-
nents of multiprotein complexes. Knockout studies have
shown that class I HDACs are involved in cell prolifera-
tion and survival [21,24]. As products of an evolutionary
recent gene duplication, HDAC1 and HDAC2 exhibit a
high degree of homology (85% identity for human pro-
teins) [18,25] and have undergone little functional diver-
gence, although specific and distinct roles have also
been identified for each of them [26,27]. For example,
targeted disruption of the Hdac1 alleles in mouse results
in cell proliferation defects and embryonic lethality by
embryonic day E9.5 [28], whereas mice lacking HDAC2
survive at least until the perinatal period [29-31]. On
the basis of their differential distributions in the brain at
distinct stages of neuroglial development, HDAC1 and
HDAC2 appear to have different functions during the
development of the central nervous system [32]. More-
over, HDAC2, but not HDAC1, negatively regulates
memory formation and synaptic plasticity [33]. Surpris-
ingly, researchers in a recent study suggested that
H D A C 1h a sap r o t e c t i v er o l ea g a i n s tt h ef o r m a t i o no f
immature teratomas with high malignant potential in
both mouse studies and human patients [34].
HDAC1 and HDAC2 form homo- and heterodimers
between each other [26,35,36], which presumably allows
them to act together or separately from each other. The
dimer is a requirement for HDAC activity [36]. Disso-
ciation of the dimer with a HDAC1 N-terminal peptide
will inhibit HDAC activity [36]. Viruses have capitalized
on this mechanism to inhibit HDAC activity. The ade-
noviral protein GAM1 inhibits HDAC1 activity by bind-
ing to the N-terminal region of HDAC1, which likely
dissociates the dimer [37].
HDAC1 and HDAC2 heterodimer levels seem to
depend on the cell type, because it was shown that 80%
to 90% of HDAC1 and HDAC2 proteins were associated
with each other in the nucleus of human breast cancer
MCF-7 cells [38], whereas 40% to 60% of HDAC1 and
HDAC2 proteins were found to be free from each other
in mouse embryonic fibroblasts [39]. Moreover, a geno-
mewide mapping study in primary human CD4
+ Tc e l l s
revealed a differential distribution of HDAC1 and
HDAC2 along regulatory and coding regions [40]. Con-
versely, HDAC1 and HDAC2 were both associated with
regulatory and coding regions in MCF-7 cells [38,41].
HDAC1 and HDAC2 relative expression levels also vary
with cell types. For example, T-lymphocyte Jurkat cells
express negligible levels of HDAC2 compared to
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HDAC2 is preferentially expressed in neurons, whereas
HDAC1 is more abundant in glial cells [32,33]. It is
likely that, at least in cells expressing markedly different
relative levels of HDAC1 and HDAC2, homodimer for-
mation would prevail over heterodimer formation.
HDAC1 and HDAC2 are both found in multiprotein
corepressor complexes Sin3, nucleosome-remodeling
HDAC (NuRD) and CoREST, which are recruited to
chromatin regulatory regions by transcription factors
(for example, Sp1, Sp3, p53, NF-B and YY1) and have
very diverse, often cell-specific, roles (Figure 1) [17,43].
Although it is generally assumed that both HDACs can
be paired within the same complex, to the best of our
knowledge, it has been demonstrated only in studies
using exogenously expressed, tagged HDAC1 and not in
studies characterizing endogenous HDAC corepressor
complexes [36]. The Sin3 core complex contains Sin3A
or Sin3B, HDAC1 and/or HDAC2, SAP18, SAP30 and
retinoblastoma-associated proteins (RbAps) RbAp46 and
RbAp48 and serves as a platform for the addition of
other modules with enzymatic functions such as nucleo-
some remodeling, DNA methylation, histone methyla-
tion and N-acetylglucosamine transferase activity
[44,45].
The NuRD complex has a variable composition that is
dependent on the cell type and external stimuli. It is the
only complex holding both HDAC- and ATP-dependent
chromatin-remodeling activities, which are carried out
by HDAC1 and/or HDAC2 and Mi-2a and/or Mi-2b,
respectively. The other known components of NuRD are
structural and/or regulatory proteins RbAp46/RbAp48
and, in some instances, also p66a or p66b, the methyl-
CpG-binding domain-containing proteins (MBD2 or
MBD3), with only MBD2 being able to recognize methy-
lated DNA and the three members of the metastasis-
associated protein family (MTA1, MTA2 or MTA3),
with different MTA proteins allowing distinct down-
stream responses to the activation of different signaling
pathways [45,46]. Lysine-specific demethylase 1 (KDM1/
LSD1) has also been identified as a component of
NuRD [47].
HDAC1 and HDAC2 are also components of the
Nanog- and Oct4-associated deacetylase (NODE) com-
plex, a NuRD-related repression complex, also compris-
ing MTA1 or MTA2, p66a or p66b,b u tn o tt h e
histone-binding proteins RbAp46/RbAp48 and the heli-
case-like ATPase Mi-2. NODE is involved in the control
o fe m b r y o n i cs t e mc e l lf a t eb yr e p r e s s i n gN a n o ga n d
Oct4 target genes [48].
Also including HDAC1 and HDAC2, but composed
of proteins distinct from those of Sin3 and NuRD, the
CoREST complex is recruited by the RE1 silencing
transcription (REST) factor, also known as the “neuro-
nal restricted silencing factor” (NRSF), to the RE1
DNA motif associated with many genes encoding fun-
damental neuronal traits. As a component of the CoR-
EST complex and as a consequence of histone H3
deacetylation, KDM1/LSD1 promotes demethylation of
H3 dimethylated on lysine 4 (H3K4me2), an event
that facilitates the formation of a repressive chromatin
structure [49,50]. Although CoREST acts as a core-
pressor in terminally differentiating nonneuronal cells
by recruiting KDM1/LSD1 to demethylate H3K4me2
and the methyltransferase G9a to methylate H3K9 at
the RE1 sites of target genes, it acts as a coactivator of
transcription in embryonic stem cells and neural stem
cells by recruiting an H3K4 methyltransferase to the
RE1 sites of target genes [51]. CoREST can also form
larger complexes by association with ZNF217, a Krüp-
pel-like zinc finger protein and strong candidate onco-
gene product found in breast cancer, or with other
complexes, such as the chromatin-remodeling complex
SWI/SNF or the C-terminal binding protein (CtBP)
complex [45,52]. Interestingly, CoREST appears to
be involved in the negative regulation of synaptic
plasticity and memory formation by HDAC2 [33].
Chromatin immunoprecipitation (ChIP) and immuno-
coprecipitation experiments performed on mouse fore-
brains showed that, though both HDAC1 and HDAC2
were incorporated in Sin3 and NuRD complexes and
were found to be enriched at the promoters of cell-
cycle genes, HDAC2 was preferentially associated with
the CoREST complex to repress neuronal gene expres-
sion [33].
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Figure 1 Class I HDAC1-HDAC2 multiprotein complexes.
Multiprotein complexes containing HDAC1-HDAC2 homo- or
heterodimers are shown. HDAC2 is shown as phosphorylated, which
is a requirement for multiprotein complex formation.
Phosphorylation is indicated by a red-outlined yellow triangle.
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tic cells and includes HDAC1, HDAC2, either one of
the related ELM-SANT proteins MIDEAS or TRERF1,
and DNTTIP1 (terminal deoxynucleotidyl transferase
(TdT)-interacting protein), although the authors who
published these findings suggested that the MiDAC
complex has a TdT-independent function in cell divi-
sion. Whether the putative histone acetylase CDYL is
also a MiDAC component is presently unclear [53].
The discussion above illustrates that the HDAC1 and
HDAC2 homo- or heterodimer can exist with different
proteins. The combination of these proteins likely deter-
mines the overall activity, substrate specificity and geno-
m i cl o c a t i o no ft h eH D A C 1a n d / o rH D A C 2c o n t a i n i n g
complex.
The two highly related complexes nuclear receptor
corepressor (NCoR or NCOR1) and silencing mediator
of retinoic acid and thyroid hormone receptor (SMRT
or NCOR2) consist of HDAC3, transducin b-like 1
(TBL1), TBL-related 1 (TBLR1) and G protein pathway
suppressor 2 (GPS2) [45,54]. NCoR and SMRT also
interact with class IIa HDACs, which exhibit no deace-
tylase activity of their own but are believed to recruit
NCoR/SMRT HDAC3 activity to distinct promoters
through their associated factors, such as myocyte enhan-
cer factor 2 (MEF2) [55]. NCoR, but not SMRT, inter-
acts with zinc finger and BTB domain-containing 33
(ZBTB33 or Kaiso), which is a protein that binds to
methylated DNA. NCoR and SMRT are regulated by
different kinase pathways and play different roles in
development. Although NCoR binds preferentially to the
thyroid hormone receptor, SMRT prefers the retinoic
acid receptor [45,54]. It is noteworthy that repression by
NCoR/SMRT is an integral phase of the cyclical process
that is the transcriptional activation of genes controlled
by liganded receptors. NCoR/SMRT repression is neces-
sary to prime chromatin for subsequent transcription
initiation [56]. TBL1 and TBLR1 are involved in the
active dismissal of corepressor complexes [54]. Besides
its role in transcriptional control, the HDAC3-NCoR-
SMRT axis is critical to the maintenance of heterochro-
matin content and genomic stability [57].
Histone deacetylation also acts in concert with the
Polycomb repressive complexes (PRC1/PRC2) or the
G9a complex, which catalyze the trimethylation of
H3K27 or H3K9, respectively. H3K27me3 is a repressive
mark that can easily be reverted, thus conferring plasti-
city to the chromatin structure. The DNA of Polycomb
target genes is generally unmethylated, but some genes
can undergo de novo DNA methylation under certain
circumstances, notably in cancer cells. H3K9me3, on the
other hand, is associated with DNA methylation and is a
stable mark, denoting permanent silencing [58,59]. As
mentioned above, the cooperation of DNA methylation
and histone deacetylation in gene silencing is also estab-
lished by the recruitment of complexes such as Sin3 or
NuRD via proteins that bind methylated DNA such as
MeCP2 or MBD2.
Class II histone deacetylases
Class II HDACs shuttle between nucleus and cytoplasm
and have tissue-specific expression and functions
[21,24,43,60]. Class IIa HDACs (HDAC4, HDAC5,
HDAC7 and HDAC9) are signal transducers character-
i z e db yt h ep r e s e n c ei nt h e ir regulatory N-terminal
domains of two or three conserved serine residues sub-
ject to reversible phosphorylation. Phosphorylation leads
to the binding of the 14-3-3 proteins, the nuclear export
of HDACs and the derepression of their target genes. A
range of kinases and phosphatases acting downstream of
diverse biological pathways have been shown to regulate
the nucleocytoplasmic trafficking of class IIa HDACs
[61]. Because of a substitution of Tyr with His in their
catalytic site, class IIa HDACs have negligible intrinsic
deacetylase activity but are able to bind acetylated lysine.
It has been suggested that, under some circumstances,
class IIa HDACs may act as bromodomains, recognizing
acetylated lysine in a sequence-dependent context and
recruiting chromatin-modifying enzymes to regulate
transcription [62]. As mentioned above, class IIa HDAC
association with MEF2 provides additional targeting for
the SMRT-NCoR complex [55]. Class IIa HDACs also
interact with numerous other transcription factors.
However, the biological relevance of these associations
has been established only for the MEF2-regulated pro-
cesses [63,64]. Class IIa HDACs are not affected by
most HDAC inhibitors at pharmacologically relevant
concentrations [62].
Class IIb HDACs (HDAC6 and HDAC10) have dupli-
cated catalytic domains, albeit the duplication is partial
in the case of HDAC10. HDAC6 and HDAC10 shuttle
between nucleus and cytoplasm, but their location is
primarily cytoplasmic. Little is known of the role of
HDAC10. HDAC6 is an a-tubulin deacetylase as well as
a cortactin deacetylase and thus is involved in the con-
trol of microtubule- and actin-dependent cell motility.
Chaperone protein HSP90 is another substrate of
HDAC6. Moreover, HDAC6 plays a critical role in the
cellular clearance of misfolded proteins via formation of
aggresomes or autophagy [43]. Thus HDAC6 is a poten-
tial therapeutic target for the treatment of an array of
diseases, including neurodegenerative diseases and can-
cer [65-67].
Class IV histone deacetylase 11
HDAC11 has sequence similarity to classes I and II
HDACs. Aside from its evolutionary conservation’s
implying a vital role across species [43] and a study
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vation and immune tolerance [68], little is known of
HDAC11 functions.
Selectivity of histone deacetylase inhibitors
T h ea c t i v es i t eo fZ n
2+-dependent HDACs consists of a
tubular pocket with two adjacent histidine residues, two
aspartic acid residues, one tyrosine residue (substituted
with histidine in class IIa HDACs, as mentioned above)
and a Zn
2+ ion at the bottom of the pocket, all forming
a charge-relay system [69]. The HDAC inhibitors cur-
rently used in clinical trials or approved by the US Food
and Drug Administration fit into this active site pocket,
owing to a pharmacophore featuring a Zn
2+-chelating
group and a linker spanning the length of the tubular
pocket and connected to a cap that blocks the active
site by interacting with the external surface of HDACs.
Depending on their chemical Zn
2+-binding group,
HDAC inhibitors belong to different classes, including
hydroxamic acids, carboxylic acids, benzamides and cyc-
lic tetrapeptides [19]. A central theme in the literature
on HDAC inhibitors is their isoform selectivity or,
rather, their perceived lack of isoform selectivity. HDAC
inhibitors have generally been considered pan-inhibitors,
inhibiting all HDACs from the classical family or class
I-specific inhibitors. This view has recently been dis-
p e l l e d ,h o w e v e r ,b yas t u d yr e v e a l i n gn ot a r g e t i n go f
class IIa HDACs by most HDAC inhibitors [62].
Although it is not known which HDAC isoform’s inhibi-
tion is responsible for the therapeutic or toxic effects
observed in clinical trials, it has generally been assumed
that the development of isoform-selective inhibitors
would result in preferable clinical outcomes. This theory
is unproven to date [20,23]. However, researchers who
have performed conventional assays have analyzed the
affinities of HDAC inhibitors for different HDACs by
using purified HDACs, whereas HDAC activity is mostly
associated with multiprotein complexes, the role and
composition of which are often cell type-specific. This
fact was taken into consideration in a pioneering study
in which the investigators carried out the chemoproteo-
mic profiling of 16 HDAC inhibitors with different che-
mical structures across six human cell lines and six
mouse tissues [53]. In that study, a nonselective HDAC
inhibitor bound to sepharose beads was added to cell
lysates under conditions that preserved the integrity of
protein complexes. In a competition assay, the mixture
was spiked with a range of concentrations of a free inhi-
bitor interfering with the capture of HDAC complexes
by the immobilized inhibitor. Captured proteins were
analyzed by quantitative mass spectrometry, and target
complexes were reconstituted by matching half-maximal
inhibitory concentration values. This initial complex
identification was further confirmed by quantitative
immunoprecipitation experiments. Although the results
collected in this study confirmed that class IIa HDACs
were not targeted by any of the studied inhibitors, they
mostly conflicted with the isoform selectivity data pre-
viously obtained in assays using purified HDACs [62,70].
This is not surprising, in view of a previous kinetic
study suggesting that the in vitro mode of action of the
HDAC inhibitor trichostatin A (TSA) depended on
whether the assay conditions preserved HDAC com-
plexes or resulted in their dissociation [71]. Incidentally,
it was also shown that TSA did not disrupt HDAC1 and
HDAC2 interaction with Sin3A [71]. However, it was
shown that TSA and suberoylanilide hydroxamic acid
(SAHA, also known as vorinostat), but not less bulky
inhibitors such as sodium butyrate or valproic acid, dis-
sociated inhibitor of growth 2 (ING2) from the Sin3
complex, thus disrupting the ING2-mediated recruit-
ment of Sin3 to chromatin [72]. Bantscheff et al. [53]
found that some inhibitors had different affinities for
different complexes. In particular, inhibitors from the
benzamide class displayed a higher affinity for the
HDAC3-NCoR complex than for NuRD and CoREST
complexes, whereas they did not target the Sin3 com-
plex. The affinity of valproic acid, an inhibitor from the
carboxylic acid class with moderate potency for class I
HDACs, was highest for the CoREST complex,
decreased gradually for the NuRD and NCoR complexes
and was lowest for the Sin3 complex [53]. The different
affinities of HDAC inhibitors detected for different com-
plexes are in agreement with the previous observation
that proteins in close proximity to the HDAC active site
could interact with the cap of HDAC inhibitors, leading
to the suggestion that HDAC-associated proteins could
specify inhibitor selectivity [73]. The class IIb enzymes
HDAC6 and HDAC10 were inhibited only by hydroxa-
mate compounds. The anti-inflammatory drug bufexa-
mac was identified as a class IIb HDAC inhibitor
(HDAC6 and HDAC10), however, and accordingly pro-
moted tubulin hyperacetylation at pharmacologically
relevant concentrations. It was shown that hyperacetyla-
tion of different HDAC substrates corresponded to the
HDAC inhibitor selectivity. For example, class I-selective
HDAC inhibitors induced histone but not tubulin
hyperacetylation, whereas nonselective HDAC inhibitors
stimulated both histone and tubulin hyperacetylation.
The authors also identified a novel mitotic HDAC com-
plex, which they called MiDAC [53]. This study provides
a new and promising path toward understanding the
mode of action of class I-specific HDAC inhibitors and
to develop isoform-selective compounds. For example,
the combination of this methodology with genomic pro-
filing of the different complexes by ChIP assay (specifi-
cally large-scale variants ChIP-on-chip and ChIP-seq)
would be highly informative.
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Inhibition of HDAC activity results in transcriptional
reprogramming, which is believed to contribute largely
to the therapeutic benefits of HDAC inhibitors on can-
cers, cardiovascular diseases, neurodegenerative disor-
ders and pulmonary diseases [24]. Inhibition of HDAC
enzymatic activity affects the expression of only 5% to
20% of genes, however, with equal numbers of genes
being upregulated and downregulated [19]. Only a frac-
tion of these changes are direct effects of HDAC inhibi-
tors, and others are downstream effects, necessitating
new protein synthesis. Only some of the direct effects
can be inferred as direct consequences of inhibition of
histone deacetylation, and others are the results of other
mechanisms, such as the inhibition of transcription fac-
tor deacetylation, resulting in an altered affinity for
DNA binding sites on target gene regulatory regions, an
altered interaction with other factors or an altered half-
life [74]. Gene expression changes and biological func-
tions targeted by HDAC inhibitors have been thoroughly
addressed in recent comprehensive reviews [21,75].
Thus only a few examples of HDAC inhibitor-induced
transcriptional changes involving novel or unexpected
mechanisms are presented below.
p21 (CDKN1A), which encodes the cyclin-dependent
kinase inhibitor p21, mediating cell cycle arrest, differ-
entiation or apoptosis, is a model gene. Its transcription
is directly upregulated in different cell types by different
HDAC inhibitors, thus contributing to the antitumor
effect of HDAC inhibitors. In parallel with transcrip-
tional activation, a reorganization of chromatin, includ-
ing histone hyperacetylation, takes place in both the
proximal and distal promoter regions [76]. p21 is regu-
lated by a variety of factors, including p53. HDAC inhi-
bitor-mediated transcriptional activation is independent
of p53, however, and consequently can occur in tumor
cells lacking a functional p53. Researchers in a recent
study demonstrated that the nucleosomal response to
the stimulation of the MAPK signaling pathway was
required for p21 induction by the HDAC inhibitor TSA.
As part of the nucleosomal response, histone H3 in the
p21 proximal promoter region was phosphorylated on
serine 10 by the mitogen- and stress-activated protein
kinase 1 (MSK1). It was shown that this phosphorylation
event was crucial to the acetylation of neighboring lysine
14. The phosphoacetylation mark was recognized by the
14-3-3ζ protein, reader of phosphoserine marks, and
was thus protected from removal by PP2A phosphatase
[77]. Presumably, 14-3-3 also acts as a scaffold for the
recruitment of chromatin remodeler, leading to initia-
tion of transcription [78]. Additionally, treatment with
the HDAC inhibitor depsipeptide, also known as romi-
depsin, can induce p21 expression by causing acetylation
of p53, protecting it from ubiquitination-induced degra-
dation and allowing the recruitment of the p300 KAT to
the p53-responsive p21 promoter [79]. The p21 gene
may generate several alternate variants [80,81]. The
impact of HDAC inhibitors on the genesis of these var-
iants remains to be determined. Some HDAC inhibitors
alter pre-mRNA splicing by changing the expression of
splicing factors, which are components of the spliceo-
some. As an example, butyrate, but not TSA, increases
the expression of SFRS2 [82]. SFRS2 is required for the
expression of p21 [82].
The induction of the Fos and Jun immediate-early
genes following the activation of the MAPK pathway is
also dependent on MSK-mediated phosphorylation of
histone H3 in the promoter region. However, the out-
come of HDAC inhibition by TSA on these genes was
opposite to the one on p21 and opposite to the common
belief that histone hyperacetylation is linked to tran-
scription activation. Treatment with TSA resulted in
rapid enhancement of H3 acetylation at the promoter
region of these genes, but transcription was inhibited
[83]. Furthermore, it was shown that continuous
dynamic turnover of acetylation was characteristic of
genes carrying the active methylation mark on H3K4,
but not of genes carrying the repressive methylation
mark on H3K9. The authors concluded that acetylation
turnover rather than stably enhanced acetylation was
crucial to the induction of the Fos and Jun genes [83]. A
similar cyclical process that entails alternating activating
and repressive epigenetic events during the hormone-
dependent activation of genes has been described [56].
Nonetheless, other scenarios are possible; for example,
the transcription activation of Fos and Jun could require
the deacetylation of a nonhistone protein associated
with their regulatory region. Investigators in several stu-
dies have suggested a role for deacetylation of transcrip-
tion factors or other proteins in gene induction [84,85].
A proposal for the role of HDACs in the basal transcrip-
tion from the mouse mammary tumor virus (MMTV)
promoter and some other TATA/Inr-containing core
promoters is that deacetylation of protein components
of the reinitiation complex would allow the recruitment
of RNA polymerase II [86].
In another example contrasting with the predominant
view of HDACs’ being transcriptional repressors, it was
shown that HDAC1 served as a coactivator for the glu-
cocorticoid receptor (GR) and that this function was
dynamically modulated by acetylation of HDAC1 itself
[87]. Researchers in a more recent study reported that
HDAC2 was also required for GR-mediated transcrip-
tional activation, and mechanistic insight was presented
regarding collaborative regulation by HDAC1 and
HDAC2 [36]. HDAC1 and HDAC2 act synergistically in
the GR-mediated transcriptional activation at the
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nor the nature of the coactivator complex with which
they associate has been identified. It was shown that the
coactivation function of HDAC1 and HDAC2 is dyna-
mically regulated by acetylation of the HDAC1 C-term-
inal tail, with K432 being an important site among the
six lysine residues that may be acetylated. It is of inter-
est to note that the C-terminal domain of HDAC1 and
HDAC2 is a region carrying modifications (phosphoryla-
tion and acetylation) that regulate HDAC activity. The
acetylation event represses the deacetylase activity of
both the HDAC1 homodimer and the HDAC1/HDAC2
heterodimer, even though only HDAC1 is acetylated
[36,87]. It was suggested that HDAC1 and HDAC2 form
homo- and heterodimers with the catalytic domains
facing each other and that this arrangement was
required for catalytic activity [36]. A modification of one
of the HDACs is all that is required to inhibit the activ-
ity of the HDAC dimer.
Epigenetic mechanisms directed by noncoding RNAs
A widespread effect of HDAC inhibitors on microRNAs
(miRNAs) levels was first reported in the breast cancer
cell line SKBr3. Following a short exposure of these
cells to a proapoptotic dose of the HDAC inhibitor
LAQ824 (also known as dacinostat), significant changes
in the levels of 40% of the miRNA population were
detected. The majority of miRNAs were downregulated,
b u ts o m ew e r eu p r e g u l a t e d[ 8 8 ] .m i R N A sa r es h o r t ,
noncoding RNAs (ncRNAs) of about 23 nucleotides that
regulate gene expression at the posttranscriptional level
by binding to the 3’-UTRs of target mRNAs, leading to
their degradation or translation repression. Although the
biogenesis of miRNAs is well-understood, little is known
of the regulation of miRNA expression, but there is
increasing evidence that miRNA expression is widely
misregulated in tumors, with tumor suppressor miRNAs
targeting growth-inducing genes being downregulated
and oncogenic miRNAs targeting growth-inhibiting
genes being upregulated [89,90].
Similarly, misregulation of miRNA expression is char-
acteristic of metastasis [91]. miRNAs are initially tran-
scribed by RNA polymerase II into long-coding or
noncoding intragenic or intergenic RNAs. They can
overlap RNA transcripts in the same, opposite or both
directions. Noncoding intragenic RNAs transcribed in
the same direction as the coding RNA can be tran-
scribed from the same promoter as the host RNA or
can have their own promoter embedded in an intron.
Promoters used by other ncRNAs are mostly unknown
[90]. Some promoters are associated with CpG islands,
which can become hypo- or hypermethylated during
tumorigenesis, resulting in transcriptional activation or
silencing, respectively. Researchers in a number of
studies have demonstrated the reversal of specific
miRNA transcriptional silencing following treatment
with DNA methyltransferase (DNMT) and/or HDAC
inhibitors, indicating that these anticancer agents can
indirectly induce posttranscriptional repression of target
genes [89,90,92-94]. Investigators in one study showed
that transcriptional silenci n go fm i R - 2 2i na c u t el y m -
phoblastic leukemia cells was independent of DNA
methylation of the CpG island within the promoter
region, but entailed K27 trimethylation of associated H3
histone. miR-22 transcriptional silencing could be
reversed by TSA treatment [95]. In acute myeloid leuke-
mia (AML), miR-223 was shown to be a direct tran-
scriptional target of the AML1/ETO fusion oncoprotein
resulting from the t(8;21) translocation. By recruiting
HDAC1, DNMT and MeCP2 activities, AML1/ETO
induces heterochromatic silencing of miR-223 [96].
Alternatively, it has been shown that miRNAs can reg-
ulate genes encoding epigenetic regulators such as
DNMT3a and DNMT3b, Polycomb-associated K-
methyltransferase EZH2 (also known as KMT6),
HDAC1 and HDAC4 [89,90]. It was determined that the
HDAC1 gene, a direct target of miR-449a, was upregu-
lated in prostate cancer cells and tissues as a conse-
quence of miR-449a downregulation [97]. Similarly,
HDAC4 targeted by miR-1-1 was upregulated in human
hepatocellular carcinoma cells and primary hepatocellu-
lar carcinoma [98]. During mouse development, HDAC4
plays a crucial role in the regulation of skeletogenesis
and myogenesis, and its expression has been shown to
be controlled at the posttranscriptional level by miR-140
and miR-1, respectively [99,100].
More recently, the existence of another class of miR-
NAs mediating transcriptional gene silencing (TGS) was
demonstrated [101,102]. Contrary to miRNA-mediated
posttranscriptional silencing, which is transient and
dependent on the sustained presence of the effector
miRNA, TGS targets promoter regions and triggers het-
erochromatin formation by inducing DNA and histone
methylation (H3K27me3 and H3K9me2), which leads to
long-term silencing. This process can be inhibited by
T S A ,i n d i c a t i n gar o l ef o rH D A C s .T h em e c h a n i s m
implicated in the chromatin reorganization in the pro-
moter region of the target gene is not fully understood,
but it is known to involve RNA-RNA pairing between
the small RNA and the nascent RNA transcript and,
among other factors, EZH2, DNMT3A and HDAC1
[103,104]. Moreover, in miRNA-induced TGS of HIV-1,
heterochromatin formation was initiated at the nuclea-
tion center, as directed by the miRNA, and was further
extended both upstream and downstream to include
adjacent genes. It was directly shown that HDAC1 was
involved in this process [105]. As a side note, miRNAs
are also able to activate transcription, notably of the
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sing a repressor miRNA [103,104].
Long, noncoding RNAs (lncRNAs) have been known
to recruit Polycomb proteins and associated HDACs to
initiate and maintain heterochromatin formation in the
silencing of developmentally important genes, such as in
X-chromosome inactivation and parental imprinting
[104,106]. It has been proposed that long, single-
stranded ncRNAs are integral components of chromatin,
which may stabilize binding of nonhistone proteins to
chromatin, such as the heterochromatin protein 1
(HP1), and/or may play a role similar to that of H1, a
linker histone contributing to the formation of higher-
order chromatin structures. It is possible that RNA
could facilitate the folding of the chromatin fiber and
the formation of loops involving long-distance interac-
tions [107].
The role of ncRNAs in the regulation of gene expres-
sion is beyond the scope of this review, but it has
become evident that the majority of protein-coding
genes are regulated by antisense RNAs and, moreover,
that a large part of the genomes of humans and other
complex organisms consist of non-protein-coding DNA
sequences, which are transcribed. It has been suggested
that these noncoding regions, previously termed “junk
DNA,” supply a vast array of ncRNAs which control the
different epigenomes supporting development and gen-
erated throughout life in response to diet and environ-
ment. There is increasing evidence that misregulation by
ncRNAs is also responsible for cancers and other dis-
eases. Furthermore, it has been proposed that ncRNAs
“provide the regulatory power and plasticity required to
program our ontogeny and cognition” [106, p1610].
Role of phosphorylation in targeting of class I histone
deacetylases
Phosphorylation of HDAC1 (S393, S421, S423),
HDAC2 (S394, S422, S424) and HDAC3 (S424) stimu-
lates enzyme activity [108,109]. In vitro HDAC2 is
phosphorylated by casein kinase (CK2), whereas
HDAC1 can be phosphorylated by CK2, cAMP-depen-
dent protein kinase and protein kinase G [25]. This
difference constitutes more evidence that, although
they share a high degree of homology, HDAC1 and
HDAC2 have distinct and separately regulated func-
tions. The regulation of HDAC1 and HDAC2 activities
by PTMs has recently been reviewed [109]. Phosphory-
lation of HDAC1 and HDAC2 is also required for their
incorporation into the Sin3, NuRD and CoREST core-
pressor complexes [25,41,110]. Recruitment of HDAC2
to regulatory regions of target genes by transcription
factors also depends on its highly phosphorylated state
[41]. On the other hand, the nonphosphorylated or
monophosphorylated HDAC2 is associated with coding
regions of transcribed genes [41] (Figure 2). Although
unmodified and monophosphorylated HDAC2 are
more abundant than highly phosphorylated HDAC2, it
is the highly phosphorylated form that is preferentially
cross-linked to chromatin with formaldehyde or cispla-
tin [111]. Thus, under conditions typically used in
ChIP, highly phosphorylated HDAC2, but not unmodi-
fied or monophosphorylated HDAC2, is preferentially
cross-linked to nuclear DNA in situ with formalde-
hyde. Through the use of a dual cross-linking ChIP
assay, however, all isoforms of HDAC1 and HDAC2
could be mapped along regulatory and coding regions
of transcribed genes, with the monophosphorylated or
unmodified HDAC2 being associated with the coding
region [41].
It should be noted that HDAC phosphorylation is
dynamic and dependent on the balance of opposing
activities of involved kinases and phosphatases. Treat-
ment of cultured cells with the protein phosphatase
inhibitor okadaic acid resulted in HDAC1 and HDAC2
hyperphosphorylation concomitant with the dissociation
of HDAC1 and HDAC2, as well as the dissociation of
HDAC1 from mSin3A or YY1. On the other hand, the
HDAC1 and HDAC2 interactions with RbAp46 or
RbAp48 were not disrupted [112]. In view of the above-
described results [25,41,110], however, it appears that
the observed dissociation of the HDAC-corepressor
complexes subsequent to okadaic acid treatment are due
not to the hyperphosphorylation of HDAC1 and
HDAC2, but rather to the hyperphosphorylation of
other unidentified factors.
Protein Phosphatase 
CK2 
Cross-links to DNA 
with formaldehyde  
Cross-link to DNA 
with DSP and formaldehyde
Bound to chromatin   Bound to chromatin  
RbAp46/48 
HDAC1  HDAC2ph  HDAC1 HDAC2 
RbAp46/48 
MBD 
p66 
MTA  Mi2 
HDAC1  HDAC2ph 
ING2 
RbAp46/48 
Sin3 
SDS 
SAP18 
SAP30 
HDAC1  HDAC2ph  HDAC1  HDAC2ph 
BHC80 
coREST 
CIBF 
LSD1 
Spliceosome 
Splicing 
factors 
Sin3 HDAC complex  NuRD HDAC complex  CoREST HDAC complex 
Figure 2 Model for the regulation of HDAC1-HDAC2 complex
formation by phosphorylation. When phosphorylated by CK2,
HDAC2 binds to the core components of Sin3, NuRD and CoREST
complexes as homodimer or heterodimer with HDAC1. In the low
or unphosphorylated states, HDAC1 and HDAC2 bind to proteins
such as the serine/arginine (SR)-rich proteins and RNA-binding
protein Hu antigen R (HuR/ELAVL1) which interact with the
spliceosome.
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strated for HDAC3. HDAC3 activity not only depends
on its binding to the NCoR/SMRT complex but also is
increased by CK2-mediated phosphorylation on S424.
Conversely, HDAC3 interaction with protein phospha-
tase 4 results in decreased activity [113]. Moreover, it
was shown that the phosphorylation state of HDAC3
had no effect on its association with NCoR or its subcel-
lular localization [113]. In a recent study in which
human HCT116 colon cancer cells were treated with
sulforaphane (SFN), a cancer chemoprotective agent
abundant in broccoli, a link between CK2-mediated
phosphorylation of HDAC3 and SMRT and the disrup-
tion of the nuclear HDAC3-SMRT corepressor complex,
followed by the export of HDAC3 into the cytoplasm,
was suggested [114]. The proposed model is that 14-3-3
and Pin1 compete with each other for binding of cyto-
plasmic phosphorylated HDAC3, with binding to 14-3-3
eventually resulting in the reentry of HDAC3 into the
nucleus and binding to Pin1 directing HDAC3 degrada-
tion. Thus extended exposure to SFN would lead to
HDAC3 degradation [114]. Again, to reconcile these
r e s u l t sw i t hp r e v i o u so n e s[ 1 1 3 ] ,i tm u s tb ea s s u m e d
that HDAC3 dissociation from SMRT and export to the
cytoplasm are due to events other than CK2-mediated
HDAC3 phosphorylation.
In the specific context of oxidative and/or nitrative
stress, such as cigarette smoke, in chronic obstructive
pulmonary disease (COPD), HDAC2 phosphorylation or
nitration was linked to its ubiquitination and degrada-
tion by proteasome [115-117]. Corticosteroids are used
to reduce inflammation in the airways of patients with
COPD. The mode of action of corticosteroids includes
the recruitment of HDAC2 and silencing of proinflam-
matory genes. However, resistance to the anti-inflamma-
tory actions of corticosteroids occurs under oxidative
and/or nitrative stress. Among a number of mechanisms
contributing to this corticosteroid insensitivity, phos-
phoinositide 3-kinase-δ- and CK2-mediated HDAC2
phosphorylation were implicated [115,116,118]. Of note,
administration of HDAC inhibitors affecting class I
HDACs should not be given to COPD patients in the
treatment of other diseases.
Role of class I histone deacetylases associated with
coding regions
Several studies have addressed the role and mode of
recruitment of class I HDACs to the coding region of
active genes. In Saccharomyces cerevisiae, the Rpd3S
HDAC complex is recruited by the chromodomain of its
EAF3 subunit and the plant homeobox domain (PHD)
of its RCO1 subunit to the H3K36me mark to deacety-
late nucleosomes behind the elongating RNA polymer-
ase II, thus preventing cryptic initiation of transcription
within the coding region [119-121]. In mammals, a
novel complex composed of SIN3B, HDAC1, the EAF3
ortholog MRG15 and the PHD finger-containing PF1 (a
homolog of yeast RCO1) was recently identified. This
complex is associated with discrete loci of constitutively
active genes and is believed to regulate RNA polymerase
II progression within transcribed regions [122].
A role of HDAC1 in alternative pre-mRNA splicing
has recently been reported in HeLa cells [123]. Alterna-
tive splicing of pre-mRNA gives rise to mature mRNA
isoforms coding for functionally different proteins. This
alternative splicing plays essential roles in differentiation
and development as well as in diseases. There has been
increasing evidence that transcription and splicing are
coupled, and recent studies have revealed the contribu-
tion of chromatin structure and histone modifications to
the selection of splice sites [124,125]. One of these stu-
dies addressed the role of HDACs in the regulation of
alternative splicing [123]. It was shown that following
treatment of HeLa cells with the HDAC inhibitor
sodium butyrate, about 4% of the genes exhibited altered
splicing. Further characterization of one of these genes,
fibronectin (FN1), indicated that HDAC inhibition
resulted in alternative exon skipping and was associated
with increased histone H4 acetylation, increased RNA
polymerase II processivity and reduced cotranscriptional
association of the splicing regulator SRp40 at the target
exon. Moreover, knockdown studies demonstrated that
HDAC1, but not HDAC2, activity was required for the
alternative splicing [123]. Although that study provided
mechanistic insight into the role of HDAC1 in alterna-
tive splicing, the question of how HDAC1 is targeted to
a particular intron-exon junction remains. It is possible
that a newly identified class of small ncRNAs, the splice
site RNAs, whose 3’ ends map precisely to the splice
donor site of internal exons in animals, serve as markers
[126]. It is noteworthy that the genes whose splicing
was affected by HDAC inhibition were all genes
involved in cell fate and differentiation [123]. One of
these genes encodes the tau protein, which is highly
expressed in the central nervous system. It turned out
that the expression of a splice variant of the tau protein
upregulated in some neurodegenerative diseases was
reduced following treatment with sodium butyrate. This
indicates that some of the therapeutic benefits of HDAC
inhibitors may be due to the modulation of alternative
splicing. Furthermore, that study [123] represents
another example of the different functions of HDAC1
and HDAC2. A recent study demonstrated that Hu pro-
teins (for example, HuR/ELAVL1), which are splicing
regulators, bind to HDAC2 and inhibit its enzyme activ-
ity. The Hu proteins are recruited to transcribed genes
by an interaction with RNA polymerase II and trans-
ferred to pre-mRNA at Hu target sites. Inhibition of
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increase in histone acetylation at specific exons [127],
increasing the transcriptional elongation rate.
Questions remain regarding the role of HDAC2 or the
presence of HDAC3 on coding regions. A genomewide
mapping study in primary human CD4
+ Tc e l l ss h o w e d
that HDAC1, HDAC2, HDAC3 and HDAC6 were
enriched in active genes. Moreover, HDAC1 and
HDAC3 were present mostly in promoter regions,
whereas HDAC2 and HDAC6 were localized to both
promoter and coding regions of active genes [40]. How-
ever, these results conflict with those of studies in which
other cell types were studied. In MCF-7 cells, HDAC1
and HDAC2 were both associated with regulatory and
coding regions [38,41]. Moreover, bufexamac, a class
IIb-specific HDAC inhibitor, did not affect the acetyla-
tion levels of histones in HeLa cells, suggesting that his-
tones are not substrates of HDAC6 [53]. Nonetheless,
the study showed that dynamic acetylation was asso-
ciated with active chromatin characterized by the H3K4
methylation mark [40]. This observation was in agree-
ment with results obtained in mouse fibroblast cells
[83,128]. A recent study in S. cerevisiae reported that
dynamic acetylation was required for the recruitment of
splicing factors during cotranscriptional spliceosome
assembly [129].
Conclusion
One major issue with HDAC inhibitors often referred to
in the literature is their lack of specificity, in particular
their lack of isoform selectivity [130]. Another issue is
the lack of known targets. There is still much to learn
about the many ways that HDAC inhibitors affect gene
expression. Indeed, we have just started to comprehend
the breadth of their actions in changing gene expression
in normal and abnormal states. New tools and methods
are continually being developed, however, leading to dis-
coveries that challenge our paradigms. For example, the
specificity of HDAC inhibitors might be directed not
toward HDAC isoforms but toward HDAC complexes.
This finding underlines the importance of resolving
HDAC interactions with other proteins and identifying
genomic targets of HDAC complexes in relevant tissues
in normal and disease states.
Classes I and II HDACs often exist as dimers. For
example, class I HDACs form heterodimers with class II
HDACs (for example, HDAC3-HDAC4). Furthermore,
class I HDAC1 and HDAC2 form either homodimers or
heterodimers. Multiprotein complexes with either an
HDAC1-HDAC2 heterodimer versus an HDAC1 or
HDAC2 homodimer may have different properties and
substrate preferences. Discovery of the mechanism regu-
lating HDAC1-HDAC 2 homo- versus heterodimer
formation in cells will be important to understanding
the biology of these enzymes.
There is still much to be learned about the mechanis-
tic linkages between class I HDACs, transcription and
RNA splicing. Whether other splicing regulators, such
as Hu proteins, regulate HDAC activity will be an
important question to address. The profound impact of
HDAC inhibitors on the alternate splicing of RNAs and
miRNAs requires further investigation to understand the
full impact of the inhibitors on the cellular spectrum of
RNAs and proteins. Recently developed mass spectro-
metry approaches are beginning to sort out the effects
of miRNAs on protein profiles. Such approaches are
required to understand the effect of HDAC inhibitor-
altered miRNA profiles on the proteome [131].
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